Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
You may not be if
Prior incisional glaucoma surgery in the study eye
Prior argon laser trabeculoplasty (ALT) in the study eye
Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Clareo Health | Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
